Literature DB >> 17474637

Hormone ablation therapy: lightening the load for today's prostate cancer patient.

Phyllis A Matthews1.   

Abstract

Prostate cancer is the most common nonskin cancer in the United States, with more than 2 million men currently living with the disease (Prostate Cancer Foundation, 2005). Hormone ablation therapy has resulted in much improved outcomes for thousands of men with this disease; however, there are often side effects that impact patients' quality of life. An overview of the use of hormone ablation therapy and the critical role nurses play for patients undergoing this treatment is provided.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17474637

Source DB:  PubMed          Journal:  Urol Nurs        ISSN: 1053-816X


  1 in total

1.  Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Steven L Highfill; Angela Panoskaltsis-Mortari; Patricia A Taylor; Richard L Boyd; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.